License and supply agreement with Genuine Health
RNS & Investor News
Launch of products at Vitafoods 2017
01 March 2017
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces it plans to launch products containing its cholesterol reducing strain (LPLDL®) at the Vitafoods Europe Trade Show ("Vitafoods") in Geneva on the 9-11 May 2017. The trade show provides opportunities to connect with 16,500 industry decision makers from the supplements, nutraceutical, functional food and beverage industries. The event is viewed as one of the world's leading trade fairs for the food and drinks industry.
OptiBiotix will be launching the first of its range of heart health products including:-
- CholBiome™: a proprietary formulation containing LPLDL® to reduce cholesterol levels and blood pressure
- CardioBiome™: a proprietary formulation containing LPLDL® to reduce a wide range of cardiovascular disease factors and improve long term heart health
The Company will also exhibit its SlimBiome® weight management technology in the New Products Zone at Vitafoods. This is the first time this product has been exhibited to an industry audience outside the UK.
The launch of heart health products follows a period in which OptiBiotix has been extending its patent portfolio, registering new trademarks (e.g. LPLDL®, Cholbiome™, Cardiobiome™) and presenting its science for peer review in publications and at scientific conferences. This has paralleled discussions with manufacturers, formulators and distribution partners to develop a range of product formulations to meet different application needs in international markets. The overall aim of this work has been to increase industry awareness of LPLDL® to develop numerous opportunities with national and international partners who have rights to specific formulations and presentations in different territories. This could create the potential for revenue streams at multiple points in the value chain including sale of the strain as an ingredient by manufacturers and royalties from the sales of higher value white label formulations and branded products.
The launch of CholBiome™ and CardioBiome™ at Vitafoods is the first of a number of heart health formulations being licensed to manufacturing and formulation partners for distribution and sale into the European market. Discussions are progressing with corporate partners for the manufacture and distribution of products containing LPLDL® in the US, Asian and other international markets.
Stephen O'Hara, CEO of OptiBiotix, commented: "OptiBiotix has made significant progress in developing, protecting, testing and raising industry awareness of its LPLDL® cholesterol and blood pressure reducing strain. This has created a high level of interest in commercialising LPLDL® both as a raw ingredient and as a component in higher value branded products. This creates the potential to generate revenues for different formulations and presentations across numerous territories at multiple points in the value chain with a mixture of national and international partners."
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP (NOMAD)
|Tel: 020 7213 0883|
Adrian Hargrave / Scott Mathieson / Kate Bannatyne (Corporate Finance)
|Tel: 020 7220 0500|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020